Comparative Pharmacology
Head-to-head clinical analysis: AKRINOL versus MICRODERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKRINOL versus MICRODERM.
AKRINOL vs MICRODERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
MICRODERM is a brand name for tretinoin, a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene transcription to promote keratinocyte differentiation, reduce proliferation, and normalize desquamation, thereby decreasing comedone formation and inflammation.
Adults: 100 mg orally twice daily.
MICRODERM is not a recognized pharmaceutical agent; no standard dosing information available.
None Documented
None Documented
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless CrCl <30 mL/min).
Terminal elimination half-life is 12 hours (range 10-15 h); requires dose adjustment in renal impairment when CrCl <30 mL/min.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Renal excretion accounts for 70% as unchanged drug, biliary/fecal elimination 20%, hepatic metabolism 10%.
Category C
Category C
Topical Retinoid
Topical Retinoid